A retrospective study investigating safety of intravitreal Ranibizumab therapy in patients with subretinal neovascularization secondary mainly to neovascular age related macular degeneration.
Phase of Trial: Phase IV
Latest Information Update: 31 Dec 2015
At a glance
- Drugs Ranibizumab (Primary)
- Indications Age-related macular degeneration; Retinal disorders
- Focus Adverse reactions
- 31 Dec 2015 New trial record